MedTrace Logo

Study of Nivolumab-Ipilimumab and cfDNA in Lung Cancer

NCT04966676 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2026-01-08

No results posted yet for this study

Summary

The purpose of this research study is to look at how effective two drugs, nivolumab and ipilimumab, are for people with non-small lung cancer that has metastasized (has spread to other parts of the body) and to see what effects these drugs have on these tumors.

Conditions

  • Non Small Cell Lung Cancer

Interventions

DIAGNOSTIC_TEST

cfDNA blood test

Blood sample will be taken for cfDNA testing

DRUG

Nivolumab

Antineoplastic agent

DRUG

Ipilimumab

Antineoplastic agent

COMBINATION_PRODUCT

Platinum-based Chemotherapy

May include carboplatin with gemcitabine, or paclitaxel or pemetrexed

Sponsors & Collaborators

Principal Investigators

  • Adrian Sacher, M.D. · Princess Margaret Cancer Centre

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-24
Primary Completion
2025-02-19
Completion
2025-02-19

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04966676 on ClinicalTrials.gov